Agouron Pharmaceuticals (AGPH) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Agouron Pharmaceuticals (AGPH)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Steve Fancy who wrote (4452)	6/10/1998 1:44:00 PM
From: Peter Singleton	of 6136

Steve, thanks for posting the weekly scrip data. Something to keep in mind is that IMS monthly share data understates Viracept's market share. IMS also provides NPA (National Prescription Audit) data which is an estimate of all-channel sales (scrips are about 2/3 of the market). For 4/98, IMS scrips NPA market share market share Viracept 31.04% 32.4% /* NPA data is from my memory Crixivan 35.1% 34.0% The walk-away points are two: 1 - Viracept is doing better vs. Crixivan than even the IMS scrips show. IMS scrips get greater airplay, and are more followed than the all-channel NPA data. 2 - AGPH is doing very well in the sales channels that don't report through IMS scrips. Says something about the quality of their sales and marketing efforts. Peter

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next